The Pharmacy Times® Cardiovascular Health Resource Center is a comprehensive resource for clinical news and expert insights on the health of the heart and blood vessels, including coronary heart disease, stroke, heart failure, heart arrhythmias, and heart valve issues.
July 9th 2025
The 2025 National Lipid Association (NLA) Scientific Sessions highlighted a strategic shift toward early, aggressive cardiometabolic intervention, underscoring the vital role of pharmacists in implementing emerging therapies and optimizing cardiovascular risk reduction.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Harnessing the Potential of SGLT2 Inhibitors in Cardiorenal Metabolic Health: Strategies for Long-term Care an...
1.0 Credit / Cardiology, Endocrinology, Diabetes, & Metabolism, Nephrology
View More
Mastering Hypertrophic Cardiomyopathy: Cutting-Edge Therapies for Better Outcomes
1.5 Credits / Cardiology
View More
Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy
1.0 Credit / Cardiology
View More
Exploring Advances in the Management of DOAC-Associated Bleeding With Reversal Agents: Role of the Health-Syst...
1.5 Credits / Cardiology, Patient Safety
View More
Optimizing LDL-C Lowering and Adherence to Hyperlipidemia Guidelines
1.0 Credit / Cardiology
View More
Hyperlipidemia Overview and the Clinical and Economic Burden
1.0 Credit / Cardiology
View More
Best Practices for Management of Hyperlipidemia: A Focus on Guidelines and Patient Adherence
0.5 Credit / Cardiology
View More
The Role of the Pharmacist in the Management of Hyperlipidemia
1.0 Credit / Cardiology
View More
Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative
1.5 Credits / Cardiology
View More
The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies
1.5 Credits / Cardiology, Rare Diseases
View More
Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies
1.5 Credits / Pulmonology, Cardiology, Rare Diseases
View More
PBM Challenges and the Evolving Role of Oncology Pharmacists in Community Practices
0.75 Credit / Oncology, Law
View More
Advancing Stroke Prevention: The Pharmacist’s Role in Implementing the 2024 Guidelines
1.0 Credit / Cardiology
View More
The Role of IV Iron in Resolving Iron Deficiency in Heart Failure
1.0 Credit / Cardiology, Gastroenterology, General Pharmacy, Oncology, Women's Health
View More
From Guidelines to Practice: The Pharmacist’s Role in Chronic Heart Failure Therapy Optimization
1.5 Credits / Cardiology
View More
Advances and Innovations in Hypertrophic Cardiomyopathy Management: A Focus on New and Emerging Therapies
1.5 Credits / Cardiology
View More
Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases
1.0 Credit / General Pharmacy, Law
View More
Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases (Pharmacy Technician Credit)
1.0 Credit / General Pharmacy, Law
View More
Identifying and Personalizing Iron Deficiency Anemia Treatment in Patients With Cancer
1.0 Credit / Cardiology, Gastroenterology, General Pharmacy, Oncology, Women's Health
View More
Managing Iron Replacement Therapies for Patients With Inflammatory Bowel Disease
1.0 Credit / Cardiology, Gastroenterology, General Pharmacy, Oncology, Women's Health
View More
Iron Deficiency Anemia Treatment Considerations in Women’s Health
1.0 Credit / Cardiology, Gastroenterology, General Pharmacy, Oncology, Women's Health
View More
Exploring ATTR Phenotypes and Identifying Appropriate Opportunities for Pharmacists to Intervene
1.0 Credits / Cardiology, Nephrology
View More
Study Affirms Safety of Anti-Clotting Drug
January 17th 2015Preliminary results of an ongoing post-marketing study examining Janssen Pharmaceuticals' rivaroxaban (Xarelto) in patients with non-valvular atrial fibrillation (NVAF) indicate that the anti-clotting drug's safety in real-world settings is consistent with the findings of previous phase 3 clinical trials.
Read More
Can an Aspirin a Day Keep Post-Atrial Fibrillation Clots Away?
January 7th 2015Roughly 50 million Americans take daily low-dose aspirin for cardioprevention, as it is generally perceived as a safe, effective, and inexpensive OTC preventive medication for cardiovascular disease. For patients who have nonvalvular atrial fibrillation, many guidelines recommend aspirin as thromboprophylaxis among those who are not considered to be high risk.
Read More
New, Personalized Online Community Helps Patients Live With Dangerous Heart Rhythm
December 11th 2014Many people experience a slight quivering or racing heart at some point and usually give it little notice. But for those diagnosed with atrial fibrillation, that irregular heartbeat can be a serious condition that can increase the risk of stroke and needs medical attention.
Read More
Cardiovascular Nutritional Supplements
December 8th 2014Various health organizations promote the importance of maintaining cardiovascular health because cardiovascular disease (CVD) is the leading cause of death among both men and women in the United States and the number of individuals with CVD continues to escalate annually.
Read More
Mild Coronary Artery Disease Puts Diabetics at Cardiovascular Risk
December 8th 2014New study results dispute the belief that diabetic patients with mild or non-obstructive coronary artery disease have a lower risk of major adverse cardiovascular events and death than their counterparts with obstructive disease.
Read More
Kynamro Reduces Risk of Cardiovascular Events in Familial Hypercholesterolemia Patients
November 19th 2014A Genzyme and Isis Pharmaceuticals Inc. study suggests that mipomersen sodium injections reduce the odds of major adverse cardiovascular events in patients with familial hypercholesterolemia, compared with the 2 years prior to therapy.
Read More
FDA Finds Increased Death Risk With Dual Antiplatelet Therapy
November 17th 2014The FDA is taking a look at a trial that showed 30 months of dual antiplatelet blood-thinning therapy decreased the risk of heart attack and clot formation in stents, yet increased the overall risk of death compared with 12 months of the treatment.
Read More
The American Heart Association awarded its 2014 Population Research Prize to Vasan R. Ramachandran, M.D., of Boston University School of Medicine, "for brilliantly seizing upon opportunities to translate cutting-edge bench science into an epidemiological context, thereby making fundamental contributions to identifying systemic markers for cardiovascular risk, both here and in developing countries."
Read More
Atrial Fibrillation Drug Approval Endorsed by FDA Committee
October 31st 2014The FDA's Cardiovascular and Renal Drugs Advisory Committee has recommended the approval of edoxaban (Savaysa) for treating patients with nonvalvular atrial fibrillation, a type of arrhythmia that can potentially cause a stroke.
Read More
Cigarette Purchases Commonly Accompany Asthma Prescription Refills
October 21st 2014Even though smoking can exacerbate respiratory conditions and limit the efficacy of their treatment, patients often purchase cigarettes while filling prescriptions for asthma or antihypertensive drugs at pharmacies.
Read More